1. Renin-angiotensin system inhibitors and risk of hepatocellular carcinoma among patients with hepatitis B virus infection
- Author
-
Chen, Ruixuan, Zhou, Shiyu, Liu, Jiao, Li, Lu, Su, Licong, Li, Yanqin, Fang, Chuyao, Zhang, Xiaodong, Luo, Fan, Gao, Qi, Lin, Yuxin, Guo, Zhixin, Cao, Lisha, Xu, Xin, and Nie, Sheng
- Subjects
Pharmacology, Experimental ,Hepatitis B -- Physiological aspects -- Complications and side effects ,Antihypertensive drugs -- Dosage and administration -- Physiological aspects -- Complications and side effects ,Hepatoma -- Risk factors -- Physiological aspects ,Health - Abstract
Background: Hepatitis B virus (HBV) infection is a common cause of liver-related morbidity and mortality. Evidence suggests that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) decrease liver fibrosis, an intermediate step between liver injury and hepatocellular carcinoma (HCC). Our aim was to investigate the association between the use of ACEIs and ARBs on incident HCC and liver-related mortality among patients with HBV infection. Methods: We conducted a population-based study on a new-user cohort of patients seen at 24 hospitals across China. We included adult patients with HBV infection who started ACEIs or ARBs (ACEIs/ARBs), or calcium channel blockers or thiazide diuretics (CCBs/THZs) from January 2012 to December 2022. The primary outcome was incident HCC; secondary outcomes were liver-related mortality and new-onset cirrhosis. We used propensity score matching and Cox proportional hazards regression to estimate the hazard ratio (HR) and 95% confidence intervals (CIs) of study outcomes. Results: Among 32 692 eligible patients (median age 58 [interquartile range (IQR) 48-68] yr, and 18 804 male [57.5%]), we matched 9946 pairs of patients starting ACEIs/ARBs or CCBs/THZs. During a mean follow-up of 2.3 years, the incidence rate of HCC per 1000 person-years was 4.11 and 5.94 among patients who started ACEIs/ARBs and CCBs/THZs, respectively, in the matched cohort. Use of ACEIs/ARBs was associated with lower risks of incident HCC (HR 0.66, 95% CI 0.50-0.86), liver-related mortality (HR 0.77, 95% CI 0.64-0.93), and new-onset cirrhosis (HR 0.81, 95% CI 0.70-0.94). Interpretation: In this cohort of patients with HBV infection, new users of ACEIs/ ARBs had a lower risk of incident HCC, liver-related mortality, and new-onset cirrhosis than new users of CCBs/THZs., Chronic hepatitis B virus (HBV) infection is a global public health concern, affecting about 296 million people. (1,2) Despite recent advances in treatment--notably, tenofovir disoproxil fumarate and entecavir--HBV remains a [...]
- Published
- 2024
- Full Text
- View/download PDF